Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bruker Cellular Analysis, Inc.CELL · Entity 109250 | Director | October 02, 2023 | October 03, 2023 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | June 17, 2026 | June 22, 2026 |
| INSULET CORPPODD · Entity 3516 | Director | May 20, 2026 | May 21, 2026 |
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | Director | June 16, 2025 | June 18, 2025 |
| Radius Health, Inc.RDUS · Entity 124173 | Director | February 20, 2020 | February 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bruker Cellular Analysis, Inc.
Report date October 02, 2023 · Filed October 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-10-02 · Exercise / conversion · Disposed 74,030 · Balance 105,207 F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2: Pursuant to the Merger, the Reporting Person disposed of each RSU held by her in exchange for the Merger Consideration. Row 2 · 2023-10-02 · Disposition to issuer · Disposed 105,207 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F4: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by her in exchange for the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration").
F2: Pursuant to the Merger, the Reporting Person disposed of each RSU held by her in exchange for the Merger Consideration.
F3: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration.
F4: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by her in exchange for the Merger Consideration.
Editas Medicine, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2036-06-16 | Direct | 51,700 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,700 · Balance 51,700 F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.
INSULET CORP
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,355 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,660 · Balance 29,355 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date June 16, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 199,907 |
Reported balance
After 2025-06-16 transaction · row 1
1 source rowRow 1 · 2025-06-16 · Grant · Acquired 89,139 · Balance 199,907 F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
Radius Health, Inc.
Report date February 20, 2020 · Filed February 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,300 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Grant · Acquired 5,500 · Balance 18,300 F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.96 · Expires 2030-02-20 | Direct | 10,000 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Grant · Acquired 10,000 · Balance 10,000 F2: The option vests in full on February 20, 2021, subject to continued service with RDUS through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date.
F2: The option vests in full on February 20, 2021, subject to continued service with RDUS through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 51,700 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001650664-26-000071 · wk-form4_1782160247.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:33 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-26-000124 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,355 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 22:24 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 89,139 | $2.16 | $192,540.24 |
DisclosureSEC source: 0001823239-25-000081 · wk-form4_1750285443.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,907 F1 · shares: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:19 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001650664-25-000103 · wk-form4_1749586773.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:06 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015648 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,695 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2026. Read SEC document |
| May 13, 2025 Filed May 14, 2025 20:15 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,235 | $0.00 Strike: $28.87 | $0.00 |
DisclosureSEC source: 0001127602-25-014271 · form4.xml · derivative · entry 3 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,235 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, which is fully vested, vested over a three-year period, with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant. Read SEC document |
| May 13, 2025 Filed May 14, 2025 20:15 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 5,235 | $317.54 | $1,662,321.90 |
DisclosureSEC source: 0001127602-25-014271 · form4.xml · nonDerivative · entry 2 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,917 Read SEC document |
| May 13, 2025 Filed May 14, 2025 20:15 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 5,235 | $28.87 | $151,134.45 |
DisclosureSEC source: 0001127602-25-014271 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:07 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,628 | $0.00 Strike: $29.87 | $0.00 |
DisclosureSEC source: 0001127602-24-023843 · form4.xml · derivative · entry 3 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,628 shares Expires 2025-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:07 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 7,628 | $225.26 | $1,718,283.28 |
DisclosureSEC source: 0001127602-24-023843 · form4.xml · nonDerivative · entry 2 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,917 Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:07 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 7,628 | $29.87 | $227,848.36 |
DisclosureSEC source: 0001127602-24-023843 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 21:14 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001650664-24-000071 · wk-form4_1717449268.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. Read SEC document |
| May 23, 2024 Filed May 24, 2024 21:58 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 20,645 | $10.78 | $222,553.10 |
DisclosureSEC source: 0001823239-24-000075 · wk-form4_1716587874.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,768 F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document |
| May 22, 2024 Filed May 23, 2024 21:08 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016459 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,917 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2025 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 13, 2024 Filed May 14, 2024 20:17 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | PurchaseCommon Stock | 45,000 | $5.64 | $253,867.50 |
DisclosureSEC source: 0001650664-24-000039 · wk-form4_1715717825.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,700 F1 · price: This transaction was executed in multiple trades at prices ranging from $5.43 to $5.83. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:31 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Disposition to issuerCommon Stock | 105,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019737 · doc4.xml · nonDerivative · entry 2 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F4 · price: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by her in exchange for the Merger Consideration. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:31 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Exercise / conversionCommon Stock | 74,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019737 · doc4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F1 · price: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2 · price: Pursuant to the Merger, the Reporting Person disposed of each RSU held by her in exchange for the Merger Consideration. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:50 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001823239-23-000065 · wf-form4_168979983995803.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,123 F1 · shares: Represents restricted stock units granted on July 17, 2023, which vest in full upon the earlier of one year from the date of grant or the date of the 2024 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001415889-23-009232 · form4-06052023_040609.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: This option was granted on June 1, 2023 and will vest in full on June 1, 2024. Read SEC document |
| May 25, 2023 Filed Jun 1, 2023 16:25 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067060 · tm2317396d6_4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,237 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. F2 · balance_after: Includes 75,642 RSUs. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:08 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016713 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,537 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0001415889-22-006490 · form4-06132022_040611.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023. Read SEC document |
| May 26, 2022 Filed Aug 1, 2022 18:48 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 32,258 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001567619-22-014734 · doc1.xml · derivative · entry 2 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,258 Underlying: Common Stock · 32,258 shares Expires 2032-05-25 F3 · derivative.exercise_date: The stock options will fully vest on May 26, 2023. Read SEC document |
| May 26, 2022 Filed Aug 1, 2022 18:48 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 19,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014734 · doc1.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,237 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 26, 2023. F2 · balance_after: Includes 29,237 RSUs. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:08 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015763 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,694 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2023 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 18:35 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | PurchaseCommon Stock | 80,000 | $6.28 | $502,400.00 |
DisclosureSEC source: 0001567619-22-006797 · doc1.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,672 Read SEC document |
| December 15, 2021 Filed Dec 20, 2021 17:40 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 9,672 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001567619-21-022346 · doc1.xml · derivative · entry 2 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,672 Underlying: Common Stock · 9,672 shares Expires 2031-12-14 F2 · derivative.exercise_date: The stock option will vest in 36 equal monthly installments until fully vested on December 15, 2024. Read SEC document |
| December 15, 2021 Filed Dec 20, 2021 17:40 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 9,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-022346 · doc1.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,672 F1 · shares: Represents an award of restricted stock units which will vest with respect to one-third of the shares on December 15, 2022, and will vest with respect to the remainder of the shares in equal quarterly installments thereafter until fully vested on December 15, 2024. The restricted stock units will be settled in shares of the Issuer's common stock upon vesting. Read SEC document |
| December 15, 2021 Filed Mar 11, 2022 18:27 UTC Amendment | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 16,507 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001567619-22-006796 · doc1.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,507 Underlying: Common Stock · 16,507 shares Expires 2031-12-14 F1 · derivative.exercise_date: The stock option will vest in 36 equal monthly installments until fully vested on December 15, 2024. F2 · balance_after: Due to a scrivener's error, the reporting person's previous form 4 filing indicated a grant of 9,672 options, which is the total amount of restricted stock units that were awarded to the reporting person and that were appropriately reflected in table I of the reporting person's previous form 4. In fact, the option grant to the reporting person was 16,507 options. This amount was also appropriately reflected in the Current Report on Form 8-K filed by Berkely Lights Inc. (the "Company") regarding the reporting person's appointment as a director of the Company. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:16 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 4,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045774 · doc4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,123 F1 · shares: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $33.36 | $0.00 |
DisclosureSEC source: 0001179110-21-006450 · edgar.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:07 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018307 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,685 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2022 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:13 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | PurchaseCommon Stock | 5,800 | $45.51 | $263,969.60 |
DisclosureSEC source: 0001179110-21-002936 · edgar.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,700 F1 · price: This transaction was executed in multiple trades at prices ranging from $45.48 to $45.59. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:52 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | PurchaseClass A Common Stock | 50,000 | $27.00 | $1,350,000.00 |
DisclosureSEC source: 0000899243-20-032216 · doc4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,852 Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 22:32 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 11,852 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031946 · doc4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,852 Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:19 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $27.49 | $0.00 |
DisclosureSEC source: 0001179110-20-007277 · edgar.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:53 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018245 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,877 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2021 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 17:57 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.96 | $0.00 |
DisclosureSEC source: 0001209191-20-012151 · doc4.xml · derivative · entry 2 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-20 F2 · derivative.exercise_date: The option vests in full on February 20, 2021, subject to continued service with RDUS through such date. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 17:57 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-012151 · doc4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,300 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $21.74 | $0.00 |
DisclosureSEC source: 0001179110-19-007682 · edgar.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 21:41 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020537 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,848 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2020 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 16:29 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 12,800 | $19.23 | $246,190.08 |
DisclosureSEC source: 0001209191-19-017351 · doc4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:02 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | PurchaseCommon Stock | 10,200 | $23.94 | $244,188.00 |
DisclosureSEC source: 0001179110-19-003510 · edgar.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,900 Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 16:06 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $17.10 | $0.00 |
DisclosureSEC source: 0001209191-19-005314 · doc4.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option shall vest in substantially equal installments on each of the first four anniversaries of January 24, 2019. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:27 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | PurchaseCommon Stock | 6,700 | $37.28 | $249,780.02 |
DisclosureSEC source: 0001179110-18-007231 · edgar.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:51 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 2,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-018180 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,122 F1 · shares: The 2,185 restricted stock units vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 1,402 restricted stock units granted on July 27, 2015, which vest on July 27, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:08 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 23,076 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001179110-18-002258 · edgar.xml · derivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2028-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2018 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on February 14, 2019 through February 14, 2021. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:32 UTC | INSULET CORP PODD · Entity 3516 | GrantStock Option (Right to Buy) · Derivative | 3,587 | $0.00 Strike: $40.60 | $0.00 |
DisclosureSEC source: 0001127602-17-018712 · form4.xml · derivative · entry 2 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,587 Underlying: Common Stock · 3,587 shares Expires 2027-05-17 Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:32 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 2,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-018712 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,937 F1 · shares: The 2,709 restricted stock units vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 2,804 restricted stock units granted on July 27, 2015, which vest 50% of the total units on July 27, 2017 and 50% of the total units on July 27, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| May 11, 2017 Filed May 12, 2017 12:33 UTC | INSULET CORP PODD · Entity 3516 | PurchaseCommon Stock | 2,580 | $38.68 | $99,782.53 |
DisclosureSEC source: 0001127602-17-017836 · form4.xml · nonDerivative · entry 1 Hopfield Jessica · CIK 0001648715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,228 F1 · price: The price reported represents the weighted average purchase price of the shares purchased. The shares were purchased at varying prices in the range of $38.6399 to $38.6792. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 2,804 restricted stock units granted on July 27, 2015, which vest 50% of the total units on July 27, 2017 and 50% of the total units on July 27, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.